LENZ Therapeutics, Inc. Files Amendment to S-1 Registration Statement

Ticker: LENZ · Form: S-1/A · Filed: Apr 9, 2024 · CIK: 1815776

Lenz Therapeutics, Inc. S-1/A Filing Summary
FieldDetail
CompanyLenz Therapeutics, Inc. (LENZ)
Form TypeS-1/A
Filed DateApr 9, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$0.00001, $3.00, $15.0299, $53.5 million, $20.33
Sentimentneutral

Sentiment: neutral

Topics: LENZ Therapeutics, S-1/A, Registration Statement, SEC Filing, Biotechnology

TL;DR

<b>LENZ Therapeutics, Inc. has filed an S-1/A amendment, updating its registration statement.</b>

AI Summary

LENZ Therapeutics, Inc. (LENZ) filed a Amended IPO Registration (S-1/A) with the SEC on April 9, 2024. LENZ Therapeutics, Inc. (formerly Graphite Bio, Inc.) filed an S-1/A amendment on April 9, 2024. The company was formerly known as Graphite Bio, Inc. and Integral Medicines, Inc. The filing relates to a registration statement under the Securities Act of 1933. The company's business address is 445 Marine View Ave Suite 320, Del Mar, CA 92014. The IRS number for the company is 844867570.

Why It Matters

For investors and stakeholders tracking LENZ Therapeutics, Inc., this filing contains several important signals. This amendment provides updated information for potential investors regarding the company's financial status and business operations. As a company that has undergone name changes, this filing clarifies its current identity and structure for regulatory and public disclosure.

Risk Assessment

Risk Level: low — LENZ Therapeutics, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, indicating ongoing regulatory processes rather than immediate financial distress or significant new risks.

Analyst Insight

Monitor future filings for details on the company's offering and business developments.

Key Numbers

  • S-1/A — Form Type (Amendment to Registration Statement)
  • 20210312 — Date of Name Change (From Graphite Bio, Inc.)
  • 20200622 — Date of Name Change (From Integral Medicines, Inc.)
  • 2024-04-09 — Filing Date (Amendment filing)

Key Players & Entities

  • LENZ Therapeutics, Inc. (company) — Filer name
  • Graphite Bio, Inc. (company) — Former company name
  • Integral Medicines, Inc. (company) — Former company name
  • 2024-04-09 (date) — Filing date
  • 445 Marine View Ave Suite 320, Del Mar, CA 92014 (address) — Business address
  • 858-925-7000 (phone) — Business phone
  • 1933 Act (regulation) — SEC Act
  • 333-278393 (file_number) — SEC File Number

FAQ

When did LENZ Therapeutics, Inc. file this S-1/A?

LENZ Therapeutics, Inc. filed this Amended IPO Registration (S-1/A) with the SEC on April 9, 2024.

What is a S-1/A filing?

A S-1/A is a amendment to an IPO registration statement, typically incorporating SEC feedback. This particular S-1/A was filed by LENZ Therapeutics, Inc. (LENZ).

Where can I read the original S-1/A filing from LENZ Therapeutics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by LENZ Therapeutics, Inc..

What are the key takeaways from LENZ Therapeutics, Inc.'s S-1/A?

LENZ Therapeutics, Inc. filed this S-1/A on April 9, 2024. Key takeaways: LENZ Therapeutics, Inc. (formerly Graphite Bio, Inc.) filed an S-1/A amendment on April 9, 2024.. The company was formerly known as Graphite Bio, Inc. and Integral Medicines, Inc.. The filing relates to a registration statement under the Securities Act of 1933..

Is LENZ Therapeutics, Inc. a risky investment based on this filing?

Based on this S-1/A, LENZ Therapeutics, Inc. presents a relatively low-risk profile. The filing is an amendment to a registration statement, indicating ongoing regulatory processes rather than immediate financial distress or significant new risks.

What should investors do after reading LENZ Therapeutics, Inc.'s S-1/A?

Monitor future filings for details on the company's offering and business developments. The overall sentiment from this filing is neutral.

How does LENZ Therapeutics, Inc. compare to its industry peers?

LENZ Therapeutics operates in the biotechnology sector, focusing on the development of therapeutics.

Are there regulatory concerns for LENZ Therapeutics, Inc.?

The filing is made under the Securities Act of 1933, which governs the registration of securities.

Industry Context

LENZ Therapeutics operates in the biotechnology sector, focusing on the development of therapeutics.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

  1. Review the full S-1/A filing for detailed business and financial information.
  2. Track future SEC filings from LENZ Therapeutics for updates on their corporate activities.
  3. Research the company's therapeutic pipeline and market potential.

Year-Over-Year Comparison

This is an amendment to a previous filing, indicating updates rather than a new initial filing.

Filing Stats: 4,591 words · 18 min read · ~15 pages · Grade level 14.9 · Accepted 2024-04-08 18:36:02

Key Financial Figures

  • $0.00001 — of common stock of New LENZ, par value $0.00001 per share ("Common Stock"), (ii) all ve
  • $3.00 — exercise price equal to or greater than $3.00 (prior to giving effect to the special
  • $15.0299 — of New LENZ Common Stock at a price of $15.0299 per share (the "PIPE Shares"), for aggr
  • $53.5 million — gregate gross proceeds of approximately $53.5 million (the "PIPE Financing"). Graphite grante
  • $20.33 — Common Stock as reported on Nasdaq was $20.33. We are an "emerging growth company,"
  • $3 billion — ed U.S. market opportunity in excess of $3 billion. It is our goal to develop and commerci

Filing Documents

Risk Factors

Risk Factors 6 Cautionary Note Regarding Forward-Looking Statements 61

Use of Proceeds

Use of Proceeds 63 Market Price of and Dividends on the Registrant's Common Equity and Related Stockholder Matters 64 Unaudited Pro Forma Condensed Combined Financials 65

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 76

Business

Business 89 Management 120

Executive Compensation

Executive Compensation 127 Certain Relationships, Related Party and Other Transactions 149 Principal Securityholders 154 Selling Securityholders 156

Description of Securities

Description of Securities 158 Plan of Distribution 161 Legal Matters 163 Experts 163 Where You Can Find Additional Information 164 Index to Financial Statements F- 1 You should rely only on the information contained in this prospectus or in any free writing prospectus prepared by us or on our behalf. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") using the "shelf" registration process. Under this shelf registration process, the selling securityholders hereunder may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such selling securityholders of the securities offered by them described in this prospectus. Neither we nor the selling securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the selling securityholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the selling securityholders will make an offer to sell these securities in any jurisdiction where the offer or sale is not permit

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.